<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D2A7E780-D923-4D61-B58E-3E467D303CA0"><gtr:id>D2A7E780-D923-4D61-B58E-3E467D303CA0</gtr:id><gtr:name>University of Adelaide</gtr:name><gtr:address><gtr:line1>Main Building</gtr:line1><gtr:line4>Adelaide</gtr:line4><gtr:line5>SA 5005</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F5B83740-823A-461B-AEB6-0DCFED1739C8"><gtr:id>F5B83740-823A-461B-AEB6-0DCFED1739C8</gtr:id><gtr:name>Kyoto University</gtr:name><gtr:address><gtr:line1>Nishikyo-ku</gtr:line1><gtr:line2>Katsura Campus</gtr:line2><gtr:line4>Kyoto</gtr:line4><gtr:line5>Kyoto, 615-8540</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Japan</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F0218A50-2D74-431E-9B66-7B583688A24A"><gtr:id>F0218A50-2D74-431E-9B66-7B583688A24A</gtr:id><gtr:name>Kumamoto University</gtr:name><gtr:address><gtr:line1>Kumamoto University</gtr:line1><gtr:line2>Honjo 1-1-1</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D2A7E780-D923-4D61-B58E-3E467D303CA0"><gtr:id>D2A7E780-D923-4D61-B58E-3E467D303CA0</gtr:id><gtr:name>University of Adelaide</gtr:name><gtr:address><gtr:line1>Main Building</gtr:line1><gtr:line4>Adelaide</gtr:line4><gtr:line5>SA 5005</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F5B83740-823A-461B-AEB6-0DCFED1739C8"><gtr:id>F5B83740-823A-461B-AEB6-0DCFED1739C8</gtr:id><gtr:name>Kyoto University</gtr:name><gtr:address><gtr:line1>Nishikyo-ku</gtr:line1><gtr:line2>Katsura Campus</gtr:line2><gtr:line4>Kyoto</gtr:line4><gtr:line5>Kyoto, 615-8540</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Japan</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F0218A50-2D74-431E-9B66-7B583688A24A"><gtr:id>F0218A50-2D74-431E-9B66-7B583688A24A</gtr:id><gtr:name>Kumamoto University</gtr:name><gtr:address><gtr:line1>Kumamoto University</gtr:line1><gtr:line2>Honjo 1-1-1</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/05C8426B-7031-44C2-B1C7-BBEC17F59739"><gtr:id>05C8426B-7031-44C2-B1C7-BBEC17F59739</gtr:id><gtr:firstName>Graham</gtr:firstName><gtr:otherNames>P</gtr:otherNames><gtr:surname>Taylor</gtr:surname><gtr:orcidId>0000-0002-3773-2390</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4E9EDD3C-8390-4CAD-8182-E2F614168FB6"><gtr:id>4E9EDD3C-8390-4CAD-8182-E2F614168FB6</gtr:id><gtr:firstName>Charles</gtr:firstName><gtr:otherNames>R M</gtr:otherNames><gtr:surname>Bangham</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK019090%2F1"><gtr:id>0BB11B2E-8A17-4FB4-BBE8-A84CE53B1BAB</gtr:id><gtr:title>Regulation of clonality in a natural retrovirus infection</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/K019090/1</gtr:grantReference><gtr:abstractText>Context

A retrovirus is a virus that integrates its DNA into the genome of the cell that it infects, where the virus can lie dormant or &amp;quot;latent&amp;quot; indefinitely. This retroviral latency is the greatest single obstacle to the eradication of a retroviral infection: although drug treatment for HIV infection is highly efficient at suppressing HIV replication, the virus is not cleared from the body because there is a reservoir of cells containing latent HIV, from which the virus reactivates if drug treatment is stopped, resulting in the development of AIDS. Understanding retroviral latency is also of critical important in the development of safe retrovirus-based viruses used in gene therapy. 

Human T lymphotropic virus type 1 (HTLV-1) is the other main disease-causing retrovirus in humans. Present mainly in the tropics, HTLV-1 causes 2 types of disease: an aggressive leukaemia, which is almost uniformly fatal, and a chronic disabling paralytic disease, which is also untreatable. There is no vaccine. 

Retroviral latency has been difficult to study in HIV infection, because HIV rapidly kills the infected cell when the virus is reactivated. HTLV-1, in contrast, does not kill the infected cell but drives it to proliferate. 

Aims

The aim of this programme is to identify how retroviral latency is regulated, to allow the virus to persist despite the host immune response and drug treatment. We have developed a sensitive, high-throughput technique to map the integration site of retroviruses in the host DNA and, crucially, to quantify accurately the abundance of each clone of infected cells. We have shown that the integration site of the retrovirus, which is different in each clone of infected cells, is a major factor that determines the abundance of that clone. In Part A of the proposed programme, we will use this new technique to identify the features of the integration site that are associated with reactivation of the virus and proliferation of the cell. To do this we will study DNA from peripheral blood taken from patients with the different diseases caused by HTLV-1. In Part B of the programme we will test specific hypotheses on the molecular mechanisms of retroviral latency: 2 hypotheses that we have already formulated, and further hypotheses that we develop from the data obtained in Part A. 

Applications and benefits

The benefits of this work will be two-fold. First, it will lead to fundamental advances in the understanding of the regulation of latency of retrovirus such as HIV and HTLV-1, and viruses used in gene therapy. Second, the ability to predict and explain why certain individuals develop serious diseases from HTLV-1 infection whereas others remain healthy will provide tools for prognosis and monitoring response to treatment of the HTLV-1-associated leukaemia and the paralytic disease. The mathematical techniques developed will be of wide application in medicine, ecology and population biology.</gtr:abstractText><gtr:technicalSummary>Objectives

i) To identify and quantify the genetic and epigenetic factors that determine the number, abundance and spontaneous proviral expression of HTLV-1-infected T cell clones in asymptomatic carriers and patients with HTLV-1 diseases; 

ii) To test mechanistic hypotheses on the regulation of HTLV-1 proviral latency in naturally-infected T cells.

Methods &amp;amp; experimental approach

i) Materials: genomic DNA from primary peripheral blood mononuclear cells from subjects with HTLV-1 infection.

Methods: High-throughput mapping and quantification of proviral integration sites in the genome (350 gDNA samples per Illumina HiSeq 2000 flow-cell). Laboratory protocols, work flow and sequences of primers and linkers are given in Gillet et al 2011. Bioinformatic, mathematical and statistical techniques are outlined in Gillet et al 2011 and extended in Berry et al 2012 (Bioinformatics 28, 755-762).

ii) Materials: Fresh primary PBMCs from HTLV-1+ subjects; HTLV-1+ CD4+ T cell clones isolated from PBMCs by limiting dilution; HTLV-1+ T cell lines. 

Methods: 
Chromatin immunoprecipitation (ChIP) to localize and quantify binding to chromatin of host proteins involved in regulating gene expression (RNA Pol II, cohesin etc) and epigenetic markers (H3K9Me3 etc). Electrophoretic mobility shift assay (EMSA) to confirm binding of proteins to proviral DNA. 
Chromosome conformation capture (3C) to detect and map chromatin loops formed between proviral DNA and host chromatin. 
Flow-sorting of cells according to stage of cell cycle.

iii) Generalized linear models; logistic regression; ordinary differential equations; standard parametric &amp;amp; non-parametric statistics.


Application &amp;amp; exploitation

We are developing a rapid, semi-quantitative assay of clonality for use in clinical management of ATLL.</gtr:technicalSummary><gtr:potentialImpactText>In addition to the academic beneficiaries, four groups will benefit from this research, in the following ways: 

1) Clinicians involved in the management of individuals with HTLV-1 infection and patients with HTLV-1 infection and the associated diseases. They will benefit through the use of assays to assist in the diagnosis, prognosis and response to therapy of HTLV-1 diseases, especially ATLL. Treatment for ATLL remains highly unsatisfactory, and there is active research involving clinical trials of novel therapeutic combinations (AZT, IFN-alpha, arsenic trioxide etc). The ability to predict who is at risk of developing ATLL and to follow the response to therapy accuarately and in real time will constitute a major advance in the management of ATLL. 

2) Clinicians and patients involved in gene therapy. Gene therapy is also at an early stage of development, and there is a strong need for improved methods to identify safe genomic harbours for therapeutic gene insertion and to monitor the results of gene therapy. Several patients have developed leukaemia following retroviral gene therapy for X-linked SCID. The previous methods available for detecting individual clones carrying a given retroviral insertion were unable to quantify clone abundance accurately, and our methods represent a significant advance in this important developing application. 

3) Patients with other retroviral infections, including notably HIV-1, will benefit from the increased understanding of the mechanisms of retroviral latency. In addition, patients with HTLV-1-infection will benefit through improved detection, diagnosis, prognosis and treatment of the malignant and inflammatory diseases associated with HTLV-1 infection. 

4) Staff working on the project will develop skills in a set of laboratory and analytical techniques that are in strong - and increasing - demand. In particular, the combination of the novel mathematical techniques and the bioinformatic analysis will find wide application in highly active fields of research. This will put the staff members in a strong position to advance their careers.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-05-03</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-11-04</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>796411</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Kumamoto</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>Impact of HTLV-1 infection on host genome</gtr:description><gtr:id>C48D3AC6-0BC6-4BE3-939B-DD026AFE5977</gtr:id><gtr:impact>The first manuscript of a scientific paper from this collaboration is now in preparation.</gtr:impact><gtr:outcomeId>544bc38fa9e1b3.64454078-1</gtr:outcomeId><gtr:partnerContribution>My collaborating partner (ex-postdoc) is a) continuing collaborative experimental work in the laboratory and b) helping us to negotiate the collection of valuable samples from other centres in Japan for our research.</gtr:partnerContribution><gtr:piContribution>I have been appointed to the Scientific Advisory Board of the International Research Center for Medical Sciences in Kumamoto.
I take part in the regular review of the research of the Institute.
One of my recent post-docs has now been appointed as a member of staff in the Institute; we maintain a close collaboration and exchange visits both Japan-UK and UK-Japan.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Adelaide</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>Impact of bronchiectasis and HBV on HTLV-1 clonality</gtr:description><gtr:id>E3419123-2E74-4090-B0E5-9400116DB339</gtr:id><gtr:impact>Scientific publications are anticipated, but this collaboration is still in its early stages.</gtr:impact><gtr:outcomeId>544bc64ed4aad3.22127527-1</gtr:outcomeId><gtr:partnerContribution>Our partner is raising further research funds in Australia, collecting the essential clinical samples, and contributing to the design and interpretation of the experiments.</gtr:partnerContribution><gtr:piContribution>We are analysing samples of clinical material provided by our collaborator; we anticipate that this will culminate in at least one original scientific publication.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Kyoto</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>HTLV-1 infection: clonality and immune response.</gtr:description><gtr:id>852CA527-66CB-4EC4-B529-A0AE59D214A4</gtr:id><gtr:impact>A major research publication was made earlier this year, including our partner as co-author: L. Cook et al. (2014): Blood 123, 3925.</gtr:impact><gtr:outcomeId>544bc54cd80934.99040159-1</gtr:outcomeId><gtr:partnerContribution>a) Our Japanese partners have given us invaluable samples of patient material for our research.
b) One postdoc from our partner's laboratory has now joined my own research group.</gtr:partnerContribution><gtr:piContribution>We have provided advice and assistance on experimental design and interpretation to the partner's group, both in correspondence and in exchange visits by senior and junior laboratory members.

I have been appointed a Visiting Professor at the Institute of Virus Research in Kyoto University.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7B628AF9-EAE4-466D-A375-C1BD109F30D5</gtr:id><gtr:title>Integration site and clonal expansion in human chronic retroviral infection and gene therapy.</gtr:title><gtr:parentPublicationTitle>Viruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a33880448444f24e79d089e007becf5"><gtr:id>0a33880448444f24e79d089e007becf5</gtr:id><gtr:otherNames>Niederer HA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1999-4915</gtr:issn><gtr:outcomeId>56a0ef29e96cf3.46584675</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F03DC06B-B001-4F50-800E-B1E50B8E43BE</gtr:id><gtr:title>Estimating T-cell repertoire diversity: limitations of classical estimators and a new approach.</gtr:title><gtr:parentPublicationTitle>Philosophical transactions of the Royal Society of London. Series B, Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/079767d0a4b0c0f8a106945b368e3781"><gtr:id>079767d0a4b0c0f8a106945b368e3781</gtr:id><gtr:otherNames>Laydon DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0962-8436</gtr:issn><gtr:outcomeId>56a0ee31648176.10024740</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBA06863-A00A-4C20-A543-2DE5EBAE4D5E</gtr:id><gtr:title>Glucose Metabolism and Oxygen Availability Govern Reactivation of the Latent Human Retrovirus HTLV-1.</gtr:title><gtr:parentPublicationTitle>Cell chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89d4835a6650adfd117a2ac4688add10"><gtr:id>89d4835a6650adfd117a2ac4688add10</gtr:id><gtr:otherNames>Kulkarni A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2451-9448</gtr:issn><gtr:outcomeId>5a2fdc179dd047.69478854</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DEADB544-7F07-4C5A-A9A7-6B501DBFE10A</gtr:id><gtr:title>T-cell receptor chain Vbeta subunit staining to quantify the malignant clone in adult T-cell leukemia</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25503a845e1e577fba542196ee434c75"><gtr:id>25503a845e1e577fba542196ee434c75</gtr:id><gtr:otherNames>Rowan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>5a578c447f3891.47767061</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F2BC7DC-3799-49A5-884D-8D187B67FCBC</gtr:id><gtr:title>Retroviruses integrate into a shared, non-palindromic DNA motif.</gtr:title><gtr:parentPublicationTitle>Nature microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3e5a301d8efbc4228233346d420a89c"><gtr:id>a3e5a301d8efbc4228233346d420a89c</gtr:id><gtr:otherNames>Kirk PD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2058-5276</gtr:issn><gtr:outcomeId>588b59c1da24b4.51766399</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28490765-B63A-4A9E-9841-EA6D9FF1DA32</gtr:id><gtr:title>HTLV-1 drives vigorous clonal expansion of infected CD8(+) T cells in natural infection.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c5aceff087dd0c51063284ddf243599"><gtr:id>2c5aceff087dd0c51063284ddf243599</gtr:id><gtr:otherNames>Melamed A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>585d61e2e79ab5.29130037</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58A27558-3AC5-4763-9F5E-0D9C8B53875C</gtr:id><gtr:title>T Cell Receptor V? Staining Identifies the Malignant Clone in Adult T cell Leukemia and Reveals Killing of Leukemia Cells by Autologous CD8+ T cells.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/579e0ab080928bfb0fd718a35b6d495d"><gtr:id>579e0ab080928bfb0fd718a35b6d495d</gtr:id><gtr:otherNames>Rowan AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>588b5de18de3e0.39857662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02BA662C-466C-4AC7-9241-2A8186DCFFCE</gtr:id><gtr:title>HTLV-1 proviral integration sites differ between asymptomatic carriers and patients with HAM/TSP.</gtr:title><gtr:parentPublicationTitle>Virology journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a33880448444f24e79d089e007becf5"><gtr:id>0a33880448444f24e79d089e007becf5</gtr:id><gtr:otherNames>Niederer HA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1743-422X</gtr:issn><gtr:outcomeId>544bc094e78604.40438115</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA314A4F-359B-43AD-B8A0-814CFA85CFE1</gtr:id><gtr:title>Genome-wide determinants of proviral targeting, clonal abundance and expression in natural HTLV-1 infection.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c5aceff087dd0c51063284ddf243599"><gtr:id>2c5aceff087dd0c51063284ddf243599</gtr:id><gtr:otherNames>Melamed A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>pm_22887_27_23555266</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D3EC1BE-FD64-4BD8-A0F5-D40765CC970E</gtr:id><gtr:title>Strongyloidiasis and infective dermatitis alter human T lymphotropic virus-1 clonality in vivo.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/466a9492063ce8d29020ef414f7dd5a6"><gtr:id>466a9492063ce8d29020ef414f7dd5a6</gtr:id><gtr:otherNames>Gillet NA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>pm_22887_27_23592987</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C8D34CD-7B72-4BB7-A7ED-4DA1F792FB41</gtr:id><gtr:title>Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Wellcome open research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc7624b4cb2de6afce45df5fbc658ebc"><gtr:id>dc7624b4cb2de6afce45df5fbc658ebc</gtr:id><gtr:otherNames>Lewin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2398-502X</gtr:issn><gtr:outcomeId>58b556eb4fbec2.05252621</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D986BB8-45FF-4892-A470-E0EC7E6F8B76</gtr:id><gtr:title>High-Throughput Mapping and Clonal Quantification of Retroviral Integration Sites.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/466a9492063ce8d29020ef414f7dd5a6"><gtr:id>466a9492063ce8d29020ef414f7dd5a6</gtr:id><gtr:otherNames>Gillet NA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>5a578b87ac92f8.81007706</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26DC83AC-80B8-424D-8AA3-534E01DACA9C</gtr:id><gtr:title>HTLV-1 clonality in adult T-cell leukaemia and non-malignant HTLV-1 infection.</gtr:title><gtr:parentPublicationTitle>Seminars in cancer biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d25d825962b27960f91cde348c7805e0"><gtr:id>d25d825962b27960f91cde348c7805e0</gtr:id><gtr:otherNames>Bangham CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1044-579X</gtr:issn><gtr:outcomeId>544bc095b761e9.44345616</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B14F986-49EC-4B3A-88FA-073E95C80045</gtr:id><gtr:title>The role of HTLV-1 clonality, proviral structure, and genomic integration site in adult T-cell leukemia/lymphoma.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1bf52149cfa6e3f76da9a3d7c85873ec"><gtr:id>1bf52149cfa6e3f76da9a3d7c85873ec</gtr:id><gtr:otherNames>Cook LB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>544bc0955a66c6.49949338</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFC00669-D607-4CAB-8B6F-A60E9D71610F</gtr:id><gtr:title>Clonality of HTLV-2 in natural infection.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c5aceff087dd0c51063284ddf243599"><gtr:id>2c5aceff087dd0c51063284ddf243599</gtr:id><gtr:otherNames>Melamed A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>544bc0958968c1.80874411</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8F55474-28CA-4318-9BA4-A1797B884145</gtr:id><gtr:title>Rapid dissemination of human T-lymphotropic virus type 1 during primary infection in transplant recipients.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1bf52149cfa6e3f76da9a3d7c85873ec"><gtr:id>1bf52149cfa6e3f76da9a3d7c85873ec</gtr:id><gtr:otherNames>Cook LB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>585d61e5f40649.52917469</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1273597-2271-4CDB-B9C0-3D37C608F74A</gtr:id><gtr:title>CADM1/TSLC1 Identifies HTLV-1-Infected Cells and Determines Their Susceptibility to CTL-Mediated Lysis.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e46e9e671d1aa2e644fbe0eb168a6bbb"><gtr:id>e46e9e671d1aa2e644fbe0eb168a6bbb</gtr:id><gtr:otherNames>Manivannan K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>585d70f1922571.57862446</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B00FA6B5-9AE1-4EE2-98FA-B9C7D901F40A</gtr:id><gtr:title>Quantification of HTLV-1 clonality and TCR diversity.</gtr:title><gtr:parentPublicationTitle>PLoS computational biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/079767d0a4b0c0f8a106945b368e3781"><gtr:id>079767d0a4b0c0f8a106945b368e3781</gtr:id><gtr:otherNames>Laydon DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-734X</gtr:issn><gtr:outcomeId>544bc0952ef3c9.06841697</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C01D5B1D-1103-40A7-8DD0-45944B448413</gtr:id><gtr:title>Human T-cell leukemia virus type 1 infects multiple lineage hematopoietic cells in vivo.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4aee1f7e6bd8bb880cc79576e5161d9"><gtr:id>c4aee1f7e6bd8bb880cc79576e5161d9</gtr:id><gtr:otherNames>Furuta R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>5a578c4368d224.25288783</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE53E6FC-E09D-43AF-855E-DDF1921A2C11</gtr:id><gtr:title>The retrovirus HTLV-1 inserts an ectopic CTCF-binding site into the human genome.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/62a04070c985b64c3a332feb370ac6e8"><gtr:id>62a04070c985b64c3a332feb370ac6e8</gtr:id><gtr:otherNames>Satou Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>585d57ab147e73.36864606</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K019090/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>